Nuvalent, Inc. (NUVL) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $99.55: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 5.33; Below-average business quality.
Nuvalent is a clinical-stage biopharmaceutical company developing precision kinase inhibitors for cancer. Its lead candidate zidesamtinib (ROS1-positive NSCLC, NDA accepted with PDUFA September 18, 2026) and neladalkib (ALK-positive NSCLC, Phase 3) target resistance, CNS... Read more
Sell if holding. Engine safety override at $99.55: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 5.33; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductzidesamtinib, neladalkib and NVL-33010-K Item 1A: 'Our future prospects are substantially dependent on zidesamtinib, neladalkib and NVL-330.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·3 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $99.55: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 5.33; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $95.30. Score 5.0/10, moderate confidence.
Take-profit target: $128.14 (+28.7% upside). Prior stop was $95.30. Stop-loss: $95.30.
Concentration risk — Product: zidesamtinib, neladalkib and NVL-330; Quality below floor (1.4 < 4.0).
Nuvalent, Inc. trades at a P/E of N/A (forward -24.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts cover NUVL with a consensus score of 4.3/5. Average price target: $142.
What does Nuvalent, Inc. do?Nuvalent is a clinical-stage biopharmaceutical company developing precision kinase inhibitors for cancer. Its lead...
Nuvalent is a clinical-stage biopharmaceutical company developing precision kinase inhibitors for cancer. Its lead candidate zidesamtinib (ROS1-positive NSCLC, NDA accepted with PDUFA September 18, 2026) and neladalkib (ALK-positive NSCLC, Phase 3) target resistance, CNS metastases, and off-target toxicities. No products are approved or generating revenue.